0 avis
Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma
Archive ouverte
Edité par CCSD -
Adoptive immunotherapy using autologous cytokine-induced killer (CIK) cells reduces the recurrence rate of hepatocellular carcinoma (HCC) in association with transarterial chemoembolization or radiofrequency. However, a largescale development of this immunotherapy remains difficult to consider in an autologous setting, considering the logistical hurdles associated with the production of this cell therapy product. A previous study has provided the in vitro and in vivo proofofconcept that allogeneic suicide genemodified killer cells (aSGMKCs) from healthy blood donors (a cell therapy product previously demonstrated to provide antileukemic effects to patients receiving allogeneic hematopoietic transplantation) may exert a potent antitumor effect towards HCC. Therefore, the development of a bank of 'readyforuse' aSGMKCs was proposed as an approach allowing for the development of immunotherapies that are more convenient and on a broader scale than that of autologous therapies. In the present study, aSGMKCs were compared with CIK cells generated according to three different protocols. Similar to CIK cells, the cytotoxic activity of aSGMKCs toward the Huh7 HCC cell line was mediated by tumor necrosis factorrelated apoptosisinducing ligand, tumor necrosis factoralpha and interferongamma. Furthermore, the frequency of natural killer (NK), NKlike T and T cells, and their in vitro and in vivo cytotoxicity activities were similar between aSGMKCs and CIK cells. Thus, the present study demonstrated that aSGMKCs are similar to CIK cells, further suggesting the possibility for future use of aSGMKCs in the treatment of solid tumors, including HCC.
Consulter en ligne
Suggestions
Du même auteur
